Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes 2025 Rethinking the Standard of Care: orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes 2025 Rethinking the Standard of Care: ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes 2025 Rethinking the Standard of Care:, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes 2025 Rethinking the Standard of Care: in your area.
Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
23.13
At ADA 2025, the SOUL trial revealed that oral semaglutide (Rybelsus) reduced the risk of major cardiovascular events—like heart attack, stroke, and CV death—by 14% over ~4 years in type 2 diabetes
21.32
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
24.71
New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral Semaglutide and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis
24.70
Congreso ACC. 25: Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
28.40
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
29.70
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
27.37
